Mode
Text Size
Log in / Sign up

IEN plus NACT shows greatest improvement in CD4+ counts among ranked strategiesNew research identifies ways to protect immune cells during cancer surgery

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider a multimodal strategy including IEN plus NACT to maintain postoperative T lymphocyte homeostasis in solid tumors.

This network meta-analysis synthesized data from 82 RCTs to evaluate various interventions, including immune-enhanced enteral nutrition combined with neoadjuvant chemotherapy (IEN+NACT), targeted therapy (TD), Enhanced Recovery After Surgery (ERAS) protocol, Transcutaneous Electrical Acupoint Stimulation (TEAS), and Dexmedetomidine (DEX). The primary objective was the maintenance of T lymphocyte subsets, specifically CD3+, CD4+, CD8+, CD4+/CD8+ ratio, and NK cells in patients with solid tumors undergoing surgery.

The analysis found that IEN+NACT resulted in the greatest improvement among ranked strategies for CD4+ counts (12.33; 95% CI 7.44-17.04). The study also assessed secondary outcomes regarding the safety of these interventions, concluding that risks associated with top-ranking interventions were acceptable.

A notable limitation is that while clinical outcomes like recovery or tumor recurrence motivated the study, they were not measured as primary endpoints in the meta-analysis. The findings suggest a multimodal strategy involving IEN, NACT, ERAS, TD, TEAS, and DEX to maintain postoperative T lymphocyte homeostasis. Clinical application should be weighed against the fact that these results are based on immunological markers rather than direct clinical outcomes.

How this fits prior evidence

This finding addresses a gap in managing the immune environment for patients with solid tumors undergoing surgery. While previous coverage noted that combining ICIs with radiotherapy improves survival and engineered constructs may overcome immunosuppressive tumor microenvironments, this study specifically focuses on maintaining T lymphocyte homeostasis through multimodal interventions like IEN+NACT, ERAS, and Dexmedetomidine.

When a patient faces surgery for a solid tumor, the body undergoes significant stress. One major concern is how this stress affects the immune system, specifically T lymphocytes. These cells are essential for your body's ability to fight off infections and manage health after an operation.

Researchers looked at 82 different trials to see which methods best protect these immune cells. They found that a combination of strategies—including specific nutrition, targeted therapy, and certain medications like Dexmedetomidine—showed the strongest results in maintaining healthy cell counts. Specifically, one group of treatments showed the greatest improvement in CD4+ counts, which are key helper cells for your immune system.

While these findings suggest a promising way to keep the immune system stable during intense treatment, it is important to remember that this study measured cell levels rather than overall recovery times or tumor recurrence. The risks associated with the top-ranking treatments were found to be acceptable. Talk with your medical team to see how these multi-step approaches might fit into a personalized care plan.

What this means for you:
A combination of nutrition and specific therapies can help maintain key immune cell levels during cancer surgery.

Common questions

What are T lymphocytes and why do they matter?

T lymphocytes, or T cells, are a type of white blood cell that is critical for your immune system. They help your body fight off infections and respond to stress. Maintaining these cells during cancer surgery is important because it helps keep the immune system balanced while the patient undergoes treatment.

Which treatments were most effective at protecting immune cells?

The study found that a combination of strategies—including enhanced nutrition, targeted therapy, and Dexmedetomidine—was highly effective. Specifically, one group showed the greatest improvement in CD4+ counts, which are essential helper cells for your immune system during surgery.

Are these treatments safe for patients with solid tumors?

The research looked at 82 different trials and found that the risks associated with the top-ranking interventions were acceptable. While the study focused on maintaining cell counts rather than overall recovery, it suggests a multi-step approach can be a viable way to support the immune system.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
Perioperative alterations in T lymphocyte subsets significantly impact tumor recurrence and postoperative recovery; therefore, identifying optimal strategies to maintain these immune parameters is essential for improving cancer surgery outcomes. The immunomodulatory effects of different tumor therapies, especially those on key T cell subsets, still lack systematic comparisons. This study aims to systematically evaluate the impact of various treatment strategies (including systemic anti-cancer therapy (SACT), nutritional support, anesthesia, analgesia, and other methods) on key immune parameters (CD3+, CD4+, CD8+ cells, CD4+/CD8+ ratio, NK cells) in patients with solid tumors and provide a comparative ranking of their efficacy. Systematic reviews and network meta-analyses were conducted on randomized controlled trials included in the PubMed, Embase and Cochrane CENTRAL databases using the PRISMA guidelines. Pairwise meta-analyses and network meta-analyses were completed using RevMan 5.3 and the gemtc package of R software. The efficacy was ranked by the area under the cumulative ranking curve (SUCRA), and the quality of the studies was evaluated using the Cochrane Risk of Bias Tool 2.0 and the Newnews-Ottawa Scale. The analysis included 82 RCTs. In maintaining T lymphocyte subsets, immune-enhanced enteral nutrition combined with neoadjuvant chemotherapy (IEN+NACT), targeted therapy (TD), the Enhanced Recovery After Surgery (ERAS) protocol, anesthesia techniques incorporating Transcutaneous Electrical Acupoint Stimulation (TEAS), and analgesia with Dexmedetomidine (DEX) ranked as the most effective strategies, with IEN+NACT showing the greatest improvement in CD4+ counts (SMD 12.33, 95% CI 7.44-17.04). Safety analysis indicated that the risks associated with these top-ranking interventions were acceptable. This network meta-analysis determined that for tumor surgery patients, the perioperative management plan should combine a multimodal strategy of IEN + NACT, ERAS, TD, TEAS and DEX to maintain postoperative T lymphocyte homeostasis and thereby protect immune function. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251233455, identifier CRD420251233455.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.